Trinity Capital Inc. Provides $50 Million in Growth Capital to Cala Health to Support Commercial Expansion of Wearable Tremor Therapy

Rhea-AI Summary

Trinity Capital (Nasdaq: TRIN) committed $50 million in growth capital to Cala Health to support commercial expansion of its wearable tremor therapy.

Cala Health commercializes the Cala kIQ System, an FDA-cleared wrist-worn device delivering individualized noninvasive nerve stimulation for essential tremor and Parkinson's disease, prescribed for at-home use to help patients perform daily activities.

Positive

• Committed $50M growth capital to Cala Health
• Cala kIQ System is FDA-cleared
• Supports commercial expansion and product innovation
• Therapy prescribed for at-home management of tremors

Negative

• None.

News Market Reaction – TRIN

+0.31%

+0.31% Session close to close

In the Apr 20 session, TRIN gained 0.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds another $50 million growth capital commitment to TRIN’s portfolio, this time ...

Analysis

This announcement adds another $50 million growth capital commitment to TRIN’s portfolio, this time backing Cala Health’s wearable neuromodulation therapy for tremors. It follows earlier portfolio growth updates, a healthcare-focused Sage Health financing, and a new joint venture, underscoring an active deployment pipeline. Investors may watch upcoming earnings, dividend sustainability, and credit performance across these new healthcare exposures to assess long-term impact.

Key Figures

Growth capital commitment: $50 million

1 metrics

Growth capital commitment $50 million Debt growth capital provided to Cala Health

Historical Context

5 past events · Latest: Fri 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Fri 10	Portfolio activity update	Positive	+0.2%	Reported Q1 2026 portfolio funding and new commitment volumes.
Wed 08	Earnings call scheduling	Neutral	+0.4%	Announced timing and access details for Q1 2026 results call.
Fri 27	Growth capital commitment	Positive	-0.6%	Committed $50M debt term loan to Sage Health for expansion.
Tue 18	Dividend declaration	Positive	+0.6%	Declared $0.17 monthly cash distributions for Q2 2026.
Mon 16	Joint venture launch	Positive	-1.2%	Formed 50/50 JV with Capital Southwest with $100M initial equity.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

TRIN’s news flow often skews positive, but reactions have been mixed, with some growth and JV announcements seeing negative next-day moves while dividends and portfolio updates saw mild gains.

Recent Company History

Over recent months, TRIN highlighted portfolio growth with $395 million in new Q1 2026 commitments and $306 million funded, announced a new joint venture with $100 million of initial equity, and declared a recurring $0.17 monthly dividend for Q2 2026. Another $50 million commitment to Sage Health reflected its lending strategy in healthcare. Today’s $50 million Cala Health financing fits this pattern of growth capital deployments.

Key Terms

bioelectronic medicine, neuromodulation, fda-cleared, noninvasive electrical stimulation

4 terms

bioelectronic medicine medical

"a bioelectronic medicine company developing wearable neuromodulation therapies for tremors."

Bioelectronic medicine uses small implanted or wearable devices to change the body’s electrical or nerve signals to prevent or treat illness instead of relying only on drugs. Think of it like a pacemaker for different organs: it can turn problematic signals up or down to relieve symptoms. For investors it matters because successful devices can open new treatment markets, offer recurring revenue from device sales and follow‑up care, and carry clear clinical and regulatory risks that affect value.

neuromodulation medical

"developing wearable neuromodulation therapies for tremors."

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

fda-cleared regulatory

"the Cala kIQ® System, an FDA-cleared wearable device designed to help patients"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

noninvasive electrical stimulation medical

"counteract tremors through noninvasive electrical stimulation."

A medical technique that uses electrical currents applied through the skin or external sensors to activate nerves or brain areas without implants or surgery, similar to using a remote control instead of rewiring a house. It matters to investors because devices and treatments labeled noninvasive usually face lower regulatory hurdles, faster adoption and different reimbursement pathways than surgical options, which can speed time to market and affect commercial scale and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHOENIX, April 20, 2026 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading international alternative asset manager, today announced the commitment of $50 million in growth capital to Cala Health ("Cala"), a bioelectronic medicine company developing wearable neuromodulation therapies for tremors.

Cala Health develops and commercializes the Cala kIQ^® System, an FDA-cleared wearable device designed to help patients manage hand tremors caused by essential tremor and Parkinson's disease. The device is worn on the wrist and measures a patient's unique tremor pattern and delivers individualized nerve stimulation to counteract tremors through noninvasive electrical stimulation. The therapy is prescribed by physicians for use at home, enabling patients to manage their symptoms outside of a clinical setting and regain the ability to perform everyday activities such as reading, writing, and eating and drinking.

"Cala Health has developed a therapy that we believe is simple, personalized, and effective for patients," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We are proud to partner with a company that is delivering meaningful improvements in patients' daily lives and look forward to supporting their continued growth and commercial expansion."

"We are pleased to partner with the Trinity team to optimize our capital structure," said Cala CEO Deanna Harshbarger. "This collaboration enhances our ability to accelerate commercial expansion and product innovation, advancing Cala TAPS® therapy to impact the lives of essential tremor and Parkinson's disease patients."

About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn.

About Cala Health
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies.

The Cala kIQ^® System is the only FDA-cleared wearable device that delivers effective therapy for action hand tremor in people with essential tremor and Parkinson's disease. The Cala kIQ device is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor. The Cala kIQ device is indicated to aid in the temporary relief of postural and kinetic hand tremor symptoms that impact some activities of daily living in the treated hand following stimulation in adults with Parkinson's disease. The Cala kIQ device with TAPS therapy delivers transcutaneous afferent patterned stimulation. To learn more, visit the website and follow Cala on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-50-million-in-growth-capital-to-cala-health-to-support-commercial-expansion-of-wearable-tremor-therapy-302745099.html

SOURCE Trinity Capital Inc.

FAQ

What did Trinity Capital announce about Cala Health on April 20, 2026 (TRIN)?

Trinity Capital committed $50 million in growth capital to Cala Health. According to Trinity Capital, the funding is intended to support Cala's commercial expansion and product innovation for wearable tremor therapy.

How will the $50 million from TRIN be used by Cala Health?

The financing is aimed at accelerating commercial expansion and product innovation. According to Cala Health, the partnership will help optimize capital structure and scale distribution of the Cala kIQ System.

What is the Cala kIQ System and is it FDA-cleared (Cala Health)?

The Cala kIQ System is a wrist-worn neuromodulation device delivering individualized nerve stimulation. According to Cala Health, the device is FDA-cleared to help manage hand tremors from essential tremor and Parkinson's disease.

Can patients use Cala TAPS therapy at home after the TRIN funding?

Yes. The therapy is prescribed for at-home use to manage tremors and daily activities. According to Cala Health, the device measures tremor patterns and delivers personalized noninvasive electrical stimulation.

What investors should know about TRIN's investment impact on Cala Health?

The $50 million commitment signals capital support for commercial growth and product development. According to Trinity Capital, the financing is intended to accelerate Cala's market expansion and innovation efforts.

Does the press release indicate regulatory or clinical setbacks for Cala Health (TRIN news)?

No regulatory or adverse clinical events were disclosed in the announcement. According to the companies, the release focuses on the capital commitment and commercial expansion of an FDA-cleared therapy.